Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Pharmacological Inhibition of Nemo-like Kinase Rescues mTOR-Mediated Translation and Primes Progenitors for Leucine-Stimulated Erythroid Expansion in Pre-Clinical Models of Diamond Blackfan Anemia

Mark C Wilkes, PhD, Jacqueline D Mercado, Mallika Saxena, Jun Chen, MD PhD, Kavitha Siva, PhD, Hee-Don Chae, PhD, Minyoung Youn, PhD, Ethan Patrick Wentworth, Kevin Jung, Ryan Sathianathen, Hiral Patel, Bertil Glader, MD PhD, Anupama Narla, MD, Claire E Repellin, PhD, Hanna T Gazda, MD PhD, Manuel Serrano, PhD, Johan Flygare, MD PhD, Kathleen M. Sakamoto, MD PhD

Blood (2019) 134 (Supplement_1): 455.

https://doi.org/10.1182/blood-2019-129570

Published: 2019

Journal Articles

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Jie Jin, MD PhD, Hongyan Tong, Yang Haiyang

Blood (2019) 134 (Supplement_1): 5387.

https://doi.org/10.1182/blood-2019-128171

Published: 2019

Journal Articles

Leukemic Stress Targets the mTOR Pathway to Suppress Residual HSC in the BM Microenvironment

John T Butler, MLS(ASCP), Sherif Abdelhamed, PhD, Lina Gao, PhD, Jeong Lim, PhD, Terzah M Horton, MD PhD, Peter Kurre, MD

Blood (2019) 134 (Supplement_1): 3730.

https://doi.org/10.1182/blood-2019-125682

Published: 2019

Journal Articles

Identification and targeting of novel CDK9 complexes in acute myeloid leukemia

Elspeth M. Beauchamp, Sameem M. Abedin, Sara G. Radecki, Mariafausta Fischietti, Ahmet Dirim Arslan, Gavin T. Blyth, Angela Yang, Connor Lantz, Alissa Nelson, Young Ah Goo, Imo Akpan, Elizabeth A. Eklund, Olga Frankfurt, Eleanor N. Fish, Paul M. Thomas, Jessica K. Altman, Leonidas C. Platanias

Blood (2019) 133 (11): 1171–1185.

https://doi.org/10.1182/blood-2018-08-870089

Published: 2019

Includes: Supplemental data

Journal Articles

Pharmacological Inhibition of Nlk (Nemo-like Kinase) Rescues Erythropoietic Defects in Pre-Clinical Models of Diamond Blackfan Anemia

Mark C Wilkes, Jun Chen, MD PhD, Kavitha Siva, PhD, Gianluca Veretti, PhD, Daniel P. Dever, PhD, Minyoung Youn, PhD, Hee-Don Chae, PhD, Jacqueline D Mercado, Mallika Saxena, Anupama Narla, MD, Bertil Glader, MD, Matthew Porteus, MD PhD, Claire E Repellin, PhD, Hanna T Gazda, MD PhD, Manuel Serrano, PhD, Johan Flygare, MD PhD, Kathleen M. Sakamoto, MD PhD

Blood (2018) 132 (Supplement 1): 754.

https://doi.org/10.1182/blood-2018-99-119954

Published: 2018

Journal Articles

Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo

Georgios Kremastiotis, Panagiotis Efentakis, Aimilia Varela, Constantinos H. Davos, Maria Tsoumani, Georgios Agrogiannis, Anastasia Konstantinidou, Eleni-Dimitra Papanagnou, Ioannis P. Trougakos, Eftathios Kastritis, Zoi Kanaki, Efstathios K. Iliodromitis, Apostolos Klinakis, Meletios A Dimopoulos, MD, Ioanna Andreadou, Evangelos Terpos, MD PhD

Blood (2018) 132 (Supplement 1): 3214.

https://doi.org/10.1182/blood-2018-99-112351

Published: 2018

Journal Articles

Role of mTORC1 and mTORC2 during Chronic Lymphocytic Leukaemia (CLL) Initiation and Progression

Natasha Malik, BSc, Karen Dunn, Owen Sansom, Prof, Alison M Michie, BSc, PhD

Blood (2018) 132 (Supplement 1): 3123.

https://doi.org/10.1182/blood-2018-99-116614

Published: 2018

Journal Articles

A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND.216

Sarit Assouline, MD, Lilian Amrein, PhD, Versha Banerji, MD FRCP, Stephen Caplan, MD, Carolyn Jane Owen, MD FRCPC, Wanda Hasegawa, MD, Sue Robinson, MD, Sudeep Shavikumar, MD, Anca Prica, MD FRCP(C), Anthea Peters, MSc, MD FRCPC, Linda Hagerman, Laura Rodriguez, Tanya Skamene, MD, Lawrence Panasci, MD, Bingshu E. Chen, Annette E Hay

Blood (2017) 130 (Supplement 1): 4319.

https://doi.org/10.1182/blood.V130.Suppl_1.4319.4319

Published: 2017

Journal Articles

Nemo-like Kinase Hyper-Activated in Erythroid Progenitors in Models of Diamond Blackfan Anemia

Mark C Wilkes, Jae Wook Lee, Sriya Kudaravalli, Anupama Narla, MD, Bertil Glader, MD, Kathleen M. Sakamoto, MD PhD

Blood (2017) 130 (Supplement 1): 78.

https://doi.org/10.1182/blood.V130.Suppl_1.78.78

Published: 2017

Journal Articles

Analysis of 54 Follicular Lymphomas By Whole Exome Sequencing Identifies Multiple Novel Recurrently Mutated Pathways

Sami N. Malek, Denzil Bernard, Zhang Xiao Ying, Luke F. Peterson, Nisar A. Amin, Shaomeng Wang, Kamlai Saiya-Cork, Mark S. Kaminski, Alfred Chang

Blood (2015) 126 (23): 112.

https://doi.org/10.1182/blood.V126.23.112.112

Published: 2015

Journal Articles

The Oral Mtor Inhibitor Everolimus in Relapsed and Refractory Hodgkin Lymphoma- Compassionate Use in 8 Centers in Brazil

Talita Silveira Da Rocha, MD, Sergio Costa Fortier, MD, Nelson Siqueira de Castro, MD, Marcia T Delamain, MD, José Salvador Oliveira, PhD, Guilherme Perini, MD, Valeria Buccheri, PhD, Rafael Dezen Gaiolla, MD, Laura Fogliato, PhD, Andressa Laranja, Maeva Pinto, MD, Carlos Chiattone, MD PhD

Blood (2015) 126 (23): 5107.

https://doi.org/10.1182/blood.V126.23.5107.5107

Published: 2015

Journal Articles

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies

Seongseok Yun, MD PhD, Nicole D. Vincelette, Katherine L. B. Knorr, PhD, Luciana L. Almada, PhD, Paula A. Schneider, Kevin L. Peterson, PhD, Karen S. Flatten, Allan D. Hess, PhD, B. Douglas Smith, MD, Judith E. Karp, MD, Martin E. Fernandez-Zapico, MD, Scott H. Kaufmann, MD PhD

Blood (2015) 126 (23): 3705.

https://doi.org/10.1182/blood.V126.23.3705.3705

Published: 2015

Journal Articles

Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients

Blood (2015) 126 (23): 816.

https://doi.org/10.1182/blood.V126.23.816.816

Published: 2015

Journal Articles

S6K1 Regulates Self-Renewal of Leukemia Initiating Cells and Normal Hematopoietic Stem Cells

Joydeep Ghosh, MSc, Anindya Chatterjee, MS,PhD, Baskar Ramdas, PhD, Michihiro Kobayashi, MD PhD, Peilin Ma, MD PhD, Yan Liu, PhD, David Plas, PhD, Reuben Kapur, PhD

Blood (2015) 126 (23): 442.

https://doi.org/10.1182/blood.V126.23.442.442

Published: 2015

Journal Articles

Co-Activation of AMPK and mTORC1 Is Synthetically Lethal in Acute Myeloid Leukemia

Blood (2014) 124 (21): 616.

https://doi.org/10.1182/blood.V124.21.616.616

Published: 2014

Journal Articles

Inorganic Polyphosphate Activates mTOR Complexes 1 and 2 in Vascular Endothelial Cells

Seyed Mahdi Hassanian Mehr, Peyman Dinarvand, Alireza R. Rezaie, PhD

Blood (2014) 124 (21): 1441.

https://doi.org/10.1182/blood.V124.21.1441.1441

Published: 2014

Journal Articles

The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide

Emily Rychak, Ph.D., Derek Mendy, B.S., Karen Miller, B.S., Jim Leisten, B.S., Rama Krishna Narla, Ph.D., Heather K Raymon, Ph.D., Rajesh Chopra, M.D., Ph.D., Antonia Lopez-Girona, Ph.D.

Blood (2013) 122 (21): 3160.

https://doi.org/10.1182/blood.V122.21.3160.3160

Published: 2013

Journal Articles

Investigating Synthetic Lethality Between mTOR Hyperactivation and Cap-Dependent mRNA Translation In a Receptor Tyrosine Kinase Driven Model Of Acute T-Cell Leukemia

Adrian Schwarzer, MD PhD, Helmut Holtmann, PhD, Celina Schauerte, M.Sc., Nomme Benn, Jan Völkel, Sabine Knöß, Johannes Zuber, MD, Zhixiong Li, MD, Axel Schambach, MD PhD, Christopher Baum, MD

Blood (2013) 122 (21): 3913.

https://doi.org/10.1182/blood.V122.21.3913.3913

Published: 2013

Journal Articles

Mechanism Of Anti-Myeloma Effects Due To Silencing Of Deptor

Yonghui Yang, PhD, Alan Lichtenstein, MD

Blood (2013) 122 (21): 4428.

https://doi.org/10.1182/blood.V122.21.4428.4428

Published: 2013

Journal Articles

High Efficiency Of the PDPK1-Inhibitor, BX912, In MCL

Grit Hutter, Yvonne Zimmermann, Vladimir Giller, Anna-Katharina Zoellner, Oliver Weigert, Wolfgang Hiddemann, M.D., Martin Dreyling

Blood (2013) 122 (21): 3077.

https://doi.org/10.1182/blood.V122.21.3077.3077

Published: 2013

NARROW

Pharmacological Inhibition of Nemo-like Kinase Rescues mTOR-Mediated Translation and Primes Progenitors for Leucine-Stimulated Erythroid Expansion in Pre-Clinical Models of Diamond Blackfan Anemia

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Leukemic Stress Targets the mTOR Pathway to Suppress Residual HSC in the BM Microenvironment

Identification and targeting of novel CDK9 complexes in acute myeloid leukemia

Pharmacological Inhibition of Nlk (Nemo-like Kinase) Rescues Erythropoietic Defects in Pre-Clinical Models of Diamond Blackfan Anemia

Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo

Role of mTORC1 and mTORC2 during Chronic Lymphocytic Leukaemia (CLL) Initiation and Progression

A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND.216

Nemo-like Kinase Hyper-Activated in Erythroid Progenitors in Models of Diamond Blackfan Anemia

Analysis of 54 Follicular Lymphomas By Whole Exome Sequencing Identifies Multiple Novel Recurrently Mutated Pathways

The Oral Mtor Inhibitor Everolimus in Relapsed and Refractory Hodgkin Lymphoma- Compassionate Use in 8 Centers in Brazil

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies

Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients

S6K1 Regulates Self-Renewal of Leukemia Initiating Cells and Normal Hematopoietic Stem Cells

Co-Activation of AMPK and mTORC1 Is Synthetically Lethal in Acute Myeloid Leukemia

Inorganic Polyphosphate Activates mTOR Complexes 1 and 2 in Vascular Endothelial Cells

The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide

Investigating Synthetic Lethality Between mTOR Hyperactivation and Cap-Dependent mRNA Translation In a Receptor Tyrosine Kinase Driven Model Of Acute T-Cell Leukemia

Mechanism Of Anti-Myeloma Effects Due To Silencing Of Deptor

High Efficiency Of the PDPK1-Inhibitor, BX912, In MCL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only